Table 1.
Baseline Patient Demographic and Disease Characteristics.
| TACE + lenvatinib + PD-1 inhibitors (n = 23) | TACE + lenvatinib (n = 32) | TACE + sorafenib (n = 29) | P-value | |
|---|---|---|---|---|
| Sex | .095 | |||
| Male | 23 (100.00) | 31 (96.88) | 25 (86.21) | |
| Female | 0 (0.00) | 1 (3.13) | 4 (13.79) | |
| Age (mean ± SD, y) | 52.83 ± 7.14 | 57.38 ± 9.44 | 55.90 ± 8.18 | .146 |
| BMI (mean ± SD) | 23.00 ± 2.96 | 23.96 ± 3.47 | 23.03 ± 3.40 | .450 |
| ECOG-PS | .928 | |||
| 0 | 12 (52.17) | 18 (56.25) | 15 (51.72) | |
| 1 | 11 (47.83) | 14 (43.75) | 14 (48.28) | |
| Hypertension | .450 | |||
| No | 17 (73.91) | 19 (59.38) | 17 (58.62) | |
| Yes | 6 (26.09) | 13 (40.63) | 12 (41.38) | |
| BCLC stage | .319 | |||
| B | 6 (26.09) | 13 (40.63) | 7 (24.14) | |
| C | 17 (73.91) | 19 (59.38) | 22 (75.86) | |
| Tumor embolus | .629 | |||
| No | 10 (43.48) | 18 (56.25) | 14 (48.28) | |
| Yes | 13 (56.52) | 14 (43.75) | 15 (51.72) | |
| Longest diameter of liver tumor (median, Q1, Q3) | 8.00(3.40,11.30) | 7.80(3.80,11.65) | 9.00(4.90,10.90) | .921 |
| Liver cirrhosis | .036 | |||
| No | 3 (13.04) | 8 (25.00) | 13 (44.83) | |
| Yes | 20 (86.96) | 24 (75.00) | 16 (55.17) | |
| Extrahepatic metastasis | .294 | |||
| No | 11 (47.83) | 22 (68.75) | 17 (58.62) | |
| Yes | 12 (52.17) | 10 (31.25) | 12 (41.38) | |
| Etiology | .116 | |||
| No | 1 (4.35) | 7 (21.88) | 4 (13.79) | |
| HBV | 22 (95.65) | 21 (65.63) | 23 (79.31) | |
| HCV | 0 (0.00) | 4 (12.50) | 2 (6.90) | |
| Child-Pugh class | .999 | |||
| A | 19 (82.61) | 27 (84.38) | 24 (82.76) | |
| B | 4 (17.39) | 5 (15.63) | 5 (17.24) | |
| Tumor node | .344 | |||
| Single | 8 (34.78) | 6 (18.75) | 6 (20.69) | |
| Multiple | 15 (65.22) | 26 (81.25) | 23 (79.31) | |
| Surgery | .722 | |||
| No | 18 (81.82) | 24 (75.00) | 24 (82.76) | |
| Yes | 4 (18.18) | 8 (25.00) | 5 (17.24) | |
| Radiotherapy | .999 | |||
| No | 21 (91.30) | 30 (93.75) | 27 (93.10) | |
| Yes | 2 (8.70) | 2 (6.25) | 2 (6.90) | |
| Ablation | .248 | |||
| No | 21 (95.45) | 27 (84.38) | 28 (96.55) | |
| Yes | 1 (4.55) | 5 (15.63) | 1 (3.45) |
Abbreviations: BCLC, Barcelona clinic liver cancer; BMI, body mass index; ECOG-PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; PD-1, programmed death 1; SD, standard deviation; TACE, transarterial chemoembolization.